Risk assessment and quality management in AIO based on CT‐linac for nasopharyngeal carcinoma: An improved FMEA and FTA approach

Guangyu Wang(Tongji University), Xiaoyan Huang(Sun Yat-sen University), Xiao Yang(Jiangsu Province Hospital), Guan‐Qun Zhou(Sun Yat-sen University), Chendi Xu(Sun Yat-sen University), Hua Li(Fujian University of Traditional Chinese Medicine), Li Chen(University of Macau), Lu Liu(Hunan University of Traditional Chinese Medicine), Ying Sun(Sun Yat-sen University), Yanfei Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Sijuan Huang(Sun Yat-sen University), Shouliang Ding(Sun Yat-sen University), Zun Piao(Sun Yat-sen University), Wenchao Diao(Sun Yat-sen University), Lecheng Jia(Shenzhen Genoimmune Medical Institute)
Medical Physics
January 10, 2025
10.1002/mp.17620
Cited by 5

Related Papers

Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak
|Science|2014|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
|Signal Transduction and Targeted Therapy|2023|627
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436